LLY Stock Risk & Deep Value Analysis
Eli Lilly and Co
Healthcare • Drug Manufacturers - General
DVR Score
out of 10
The Bottom Line on LLY
We analyzed Eli Lilly and Co using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran LLY through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Here's what we found.
LLY Stock Risk Analysis
Overall Risk
Moderate
Financial Risk
Low
Market Risk
Low
About Eli Lilly and Co (LLY)
Sector
Healthcare
Industry
Drug Manufacturers - General
Market Cap Category
mega
Market Cap
$965.02B
LLY Deep Value Analysis
Compare LLY to Similar Stocks
See how Eli Lilly and Co stacks up against related companies in our head-to-head analysis.
LLY Red Flags & Warning Signs
- âš
Stronger-than-expected competition in GLP-1 market from Novo Nordisk or new entrants
- âš
Unexpected clinical trial failures or regulatory setbacks for key pipeline candidates
- âš
Increased drug pricing pressure from governments or payers
- âš
Patent cliffs for current blockbuster drugs in the late 2020s/early 2030s
Unlock LLY Red Flags & Risk Warnings
Create a free account to see the full analysis
LLY Financial Health Metrics
Market Cap
$965.02B
P/E Ratio
52.64
LLY Competitive Moat Analysis
Sign in to unlockMoat Rating
Wide
Moat Trend
Expanding
Moat Sources
4 Identified
Eli Lilly's wide moat is durable due to its extensive patent portfolio covering blockbuster drugs, ongoing investment in a diverse R&D pipeline that consistently generates new intellectual property, significant manufacturing scale which creates cost advantages, and strong brand loyalty within the medical community. The high cost and complexity of drug development and regulatory approval also serve as substantial barriers to entry.
LLY Competitive Moat Analysis
Sign up to see competitive advantages
LLY Catalysts & Growth Drivers
Near-Term (0-6 months)
- •Q4 2025 Earnings Report (Estimated late Jan/early Feb 2026)
- •Key clinical trial readouts for pipeline assets (e.g., Donanemab for Alzheimer's, new GLP-1 indications)
- •Manufacturing capacity expansion updates for Mounjaro/Zepbound
Medium-Term (6-18 months)
- •Global market expansion for Mounjaro/Zepbound, including new geographies and indications
- •Progression of novel oncology or immunology assets through late-stage trials
- •Strategic partnerships to enhance R&D capabilities or market access
Long-Term (18+ months)
- •Sustained leadership in metabolic diseases and potential expansion into adjacent therapeutic areas
- •Successful commercialization of next-generation therapies, particularly in neuroscience
- •Leveraging AI and advanced analytics for drug discovery and development
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
LLY Bull Case: What Could Go Right
- ✓
Sustained double-digit sales growth of Mounjaro/Zepbound and successful expansion into new indications/geographies
- ✓
Positive clinical trial results and regulatory approvals for key pipeline candidates (e.g., Donanemab)
- ✓
Continued R&D productivity and successful advancement of next-generation therapies
Bull Case Analysis
See what could go right with Premium
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research and consult with a qualified financial advisor.
